falsefalse

Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC - Episode 1

The State of Targeted Therapies in NSCLC

,

Explore the current landscape of targeted therapies in non-small cell lung cancer, focusing on KRAS G12C mutations, molecular testing, and current treatments.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: The State of Targeted Therapies in NSCLC
    EP. 2: Frontline Treatments for KRAS G12C-Mutation mNSCLC
    EP. 3: Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations
    EP. 4: The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC
    EP. 5: Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition
    EP. 6: Disease Progression Beyond Frontline KRAS G12C Inhibitors
    EP. 7: CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC
    EP. 8: KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC
    EP. 9: Practical Management of Hepatotoxicity in KRAS G12C Inhibitors
    EP. 10: Future Perspectives in KRAS G12C-Mutated NSCLC

    Related Content:

    Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLCLung CancerInsights
    Zongertinib Could Alter SOC in HER2-Mutated Advanced NSCLC
    Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC
    Adjuvant Aumolertinib Boosts DFS in Stage II-IIIB, EGFR-Mutated NSCLC
    x